Drug Overview
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone. The drug is being investigated for a number of indications including major depressive disorder, post-partum depression, insomnia, and bipolar depression.
Analyst Outlook
Forecast as having blockbuster potential, SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is an exciting prospect in the depression pipeline. SAGE-217 is the oral formulation of SAGE Therapeutics’ brexanolone franchise. The drug boasts prominent novelty and targets unmet need in multiple respects: its mechanism of action; its efficacy in post-partum depression (PPD); its rapidacting effects; and its episodic, short-course dosing schedule. The company is investing in a broad development program for SAGE217, encompassing PPD, major depressive disorder (MDD), and MDD with co-morbid insomnia, and there is much enthusiasm for the drug.
SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors and shares similar pharmacology properties to brexanolone. The drug is being investigated for a number of indications including major depressive disorder, post-partum depression, insomnia, and bipolar depression.
Analyst Outlook
Forecast as having blockbuster potential, SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is an exciting prospect in the depression pipeline. SAGE-217 is the oral formulation of SAGE Therapeutics’ brexanolone franchise. The drug boasts prominent novelty and targets unmet need in multiple respects: its mechanism of action; its efficacy in post-partum depression (PPD); its rapidacting effects; and its episodic, short-course dosing schedule. The company is investing in a broad development program for SAGE217, encompassing PPD, major depressive disorder (MDD), and MDD with co-morbid insomnia, and there is much enthusiasm for the drug.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
